Insider Selling: Protagonist Therapeutics Inc (PTGX) Major Shareholder Sells 1,204 Shares of Stock

Protagonist Therapeutics Inc (NASDAQ:PTGX) major shareholder X L.P. Canaan sold 1,204 shares of Protagonist Therapeutics stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $20.84, for a total transaction of $25,091.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

X L.P. Canaan also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Thursday, March 22nd, X L.P. Canaan sold 39,518 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $20.61, for a total transaction of $814,465.98.
  • On Monday, March 19th, X L.P. Canaan sold 20,365 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $20.55, for a total transaction of $418,500.75.
  • On Thursday, March 15th, X L.P. Canaan sold 13,155 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $20.66, for a total transaction of $271,782.30.

NASDAQ PTGX opened at $8.78 on Friday. Protagonist Therapeutics Inc has a 1 year low of $7.85 and a 1 year high of $23.97.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Wednesday, March 7th. The company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.19. The firm had revenue of $11.28 million during the quarter, compared to the consensus estimate of $8.75 million. equities research analysts predict that Protagonist Therapeutics Inc will post -0.66 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of PTGX. California State Teachers Retirement System raised its stake in Protagonist Therapeutics by 8.5% during the second quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock worth $188,000 after acquiring an additional 1,300 shares in the last quarter. Wells Fargo & Company MN raised its stake in Protagonist Therapeutics by 60.8% during the third quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock worth $169,000 after acquiring an additional 3,617 shares in the last quarter. TIAA CREF Investment Management LLC raised its stake in Protagonist Therapeutics by 19.5% during the second quarter. TIAA CREF Investment Management LLC now owns 23,372 shares of the company’s stock worth $264,000 after acquiring an additional 3,812 shares in the last quarter. Teachers Advisors LLC raised its stake in Protagonist Therapeutics by 33.1% during the fourth quarter. Teachers Advisors LLC now owns 21,593 shares of the company’s stock worth $449,000 after acquiring an additional 5,375 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in Protagonist Therapeutics by 1,086.0% during the fourth quarter. Bank of Montreal Can now owns 5,930 shares of the company’s stock worth $123,000 after acquiring an additional 5,430 shares in the last quarter. Institutional investors and hedge funds own 56.08% of the company’s stock.

Several brokerages have recently issued reports on PTGX. BidaskClub downgraded shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Zacks Investment Research raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a report on Tuesday, March 13th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $13.00 price objective (down previously from $42.00) on shares of Protagonist Therapeutics in a report on Monday, March 26th. They noted that the move was a valuation call. Finally, Stifel Nicolaus assumed coverage on shares of Protagonist Therapeutics in a report on Monday, January 29th. They issued a “buy” rating and a $32.00 price objective for the company. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $26.75.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Protagonist Therapeutics Inc (PTGX) Major Shareholder Sells 1,204 Shares of Stock” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/protagonist-therapeutics-inc-ptgx-major-shareholder-x-l-p-canaan-sells-1204-shares.html.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Insider Buying and Selling by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply